Dr. Crowe is Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center. He is a board-certified pediatric infectious diseases physician and viral immunology researcher. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. His research group uses a very broad array of techniques including molecular and cellular biology, state-of-the-art imaging and flow cytometry, bioinformatics, and bioengineering approaches to attack scientific problems at the forefront of immunity research. He is an elected member of the National Academy of Medicine and National Academy of Inventors, is an ISI Highly Cited Researcher and has been the recipient of numerous investigator awards including the 2019 Merck Future Insight Prize, 2020 AAAS Golden Goose Award, and others. Many vaccine candidates and human monoclonal antibodies developed during his team’s research have been tested in Phase I-III clinical trials in humans, including tixagevimab + cilgavimab (Evusheld) that obtained EUA from the US FDA for preventing COVID-19 and has been given to over a million patients in the US, Europe, Middle East, Africa and Australia.
Dr. Crowe attended Davidson College in NC where he obtained a BS, followed by medical school and pediatrics residency at UNC Chapel Hill. He trained for five years as a postdoctoral fellow in virology, immunology, and vaccine sciences in the NIH intramural program in Bethesda, MD with Robert Chanock, a National Academy member and the most notable protégé of Albert Sabin. Five of the live attenuated vaccines for respiratory syncytial virus (RSV) Dr. Crowe made at the NIH have been tested in Phase I and II clinical trials. At Vanderbilt, he completed a fellowship in Pediatric Infectious Diseases.
He also is Founder of the biotech company IDBiologics and Chairman and Chief Scientific Officer of the nonprofit Global Pandemic Prevention and Biodefense Center, home of the AHEAD100 initiative to discover and stockpile human monoclonal antibodies for the 100 most likely causes of future epidemics.